Galmed Pharmaceuticals' First Quarter Results Showcase Financial Stability and Promising Research Developments Galmed Pharmaceuticals announced financial results for Q1 2025, highlighting growth in research and developments. With a solid cash balance and reduced net loss, Galmed is poised for future advancements.

Galmed Pharmaceuticals' First Quarter Results Showcase Financial Stability and Promising Research Developments #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #NASDAQ_GLMD

Galmed Pharmaceuticals' Comprehensive Annual Report: Key Insights and Future Directions Galmed Pharmaceuticals has released its Annual Report on Form 20-F for the fiscal year ending December 31, 2024, outlining significant developments and future strategies.

Galmed Pharmaceuticals' Comprehensive Annual Report: Key Insights and Future Directions #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #NASDAQ_GLMD